Maarten Tushuizen
Gastroenterologist & hepatologist, Leiden University Medical Center
Sponsored by:
Date: April 21, 2022 (Thursday)
Time: New York 10:30 | London 15:30 | Paris 16:30 | Singapore 22:30 | Tokyo 23:30 | Sydney 00:30 (22nd April)
Duration: 90 minutes
Event structure: 3 x 30-minute sessions consisting of a 20-minute presentation + a 10-minute discussion
Registration fee: Complimentary access
Webinar on-demand: Available to view until 6 May 2022 (registration is required)
Prof. Stefan D. Anker, MD, PhD, FESC (Charité Berlin) will chair the first webinar in a series of two on the topic: Getting to the heart of NAFLD/NASH – the cardiovascular perspective.
This webinar series consisting of three presentations with interactive discussions will cover the following topics:
• What is NAFLD/NASH? (Maarten Tushuizen, Leiden University Medical Center)
– Definition & disease spectrum
– Epidemiology
– Comorbidities
– Natural progression
• NAFLD/NASH and the Heart (Onno Holleboom, Amsterdam University Medical Center)
– Role of NAFLD/NASH in CVD
– Pathophysiology
• Managing Patients with CVD & NAFLD/NASH (Sven Francque, University Hospital Antwerp)
– Screening
– Referral
– Treatment strategies
– CV drugs in patients with NAFLD/NASH
This webinar can be followed as the complete series of 3 x 30 minutes sessions but participants are also encouraged to pick and choose the specific topics appealing to their clinical practice or field of interest.
PRESENTERS AND MODERATOR:
PRESENTERS:
Dr. Maarten Tushuizen – Gastroenterologist & hepatologist, Leiden University Medical Center
Dr. Maarten Tushuizen is a gastroenterologist & hepatologist at the Leiden University Medical Center. His research focusses on NAFLD/NASH, principally development of clinical care paths including diagnostics, surveillance and treatment. Furthermore, his interests are the various aspects (including prevention) of NAFLD/NASH before and after liver transplantation, including posttransplantation diabetes mellitus, hepatocellular carcinoma and cardiovascular disease risk.
Dr. Onno Holleboom, MD, PhD – Internist, faculty member & Principal Investigator, Amsterdam University Medical Center
Dr. Onno Holleboom, MD, PhD is an internist registered in Vascular Medicine and Endocrinology, faculty member of the Department of Vascular Medicine and Principal Investigator at Amsterdam UMC. He initiated a multidisciplinary outpatient clinic for NAFLD together with hepatology and including clinical trials. Within the NAFLD-NL consortium and supported by the MLDS foundation, he aims to develop care paths for NAFLD together with LUMC and Radboud MC. Together with prof. Max Nieuwdorp, he runs a research group with 6 PhD candidates focussing on genetic and gut microbial drivers of NAFLD in three cohort studies, as well as more fundamental work on lipid droplet and inflammatory pathways. He has published 60 peer-reviewed articles, including in Circulation and Cell Metabolism and received various prestigious grants, a.o. from The Netherlands Organization for Scientific Research and the Amsterdam UMC Fellowship.
Prof. Dr. Sven Francque, Chairman & Professor, University Hospital Antwerp & University of Antwerp
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission. He participates in several clinical trials in the field and was/is as scientific committee member involved in the design of several phase 2 and phase 3 trials in NAFLD. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp.
MODERATOR:
Prof. Stefan D. Anker, MD, PhD, FESC – Professor of (Tissue)Homeostasis in Cardiology & Metabolism, Charité Berlin
Prof. Stefan Anker, MD, PhD, FESC is Professor of (Tissue)Homeostasis in Cardiology & Metabolism at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor of Cardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014-17). Dr. Anker has authored more than 1,000 articles (total citations: >217,000, h-index: 179, papers with ≥300 citations: 113; source: GoogleScholar, 14. Jan., 2022) and was named Highly Cited Researcher 2015–2021.
About AwareNASH:
AwareNASH (https://awarenash.eu/) is a research and educational project with the objective to educate clinicians managing patients with NAFLD and NASH on the importance of prompt diagnosis (especially in the case of NASH), along with the relationship of NAFLD/NASH to metabolic disease and CVD.
The Scientific Committee consists of multi-disciplinary experts based in prestigious European University Hospitals. The project is funded by an independent educational grant provided by Pfizer.
With over a decade of experience in hosting life science events, Global Engage is your ideal partner to either devise an agenda for you or work with you and your speakers to promote the online event to our extensive databases.
For further details please contact
Gavin Hambrook
Telephone +44 (0) 7538 368 764 or
email [email protected]
Reuben Raj
Telephone: +603 2117 5193 or
email [email protected]
